viernes, 17 de febrero de 2017

CDRH Industry: REMINDER: Webinar on Factors to Consider When Making Benefit-Risk Determinations for Medical Device IDEs Final Guidance

FDA Logo
On January 12, 2017, the FDA published a final guidance clarifying key factors it considers when assessing the benefits and risks of Investigational Device Exemption (IDE) submissions for human clinical study. 
The final guidance:
  • Enhances the predictability, consistency and transparency of the IDE review process;
  • Provides a common understanding between the FDA staff and clinical trials sponsors on what information is critical to the benefit-risk assessment of an IDE submission; and
  • Facilitates the incorporation of evidence and knowledge from different domains—clinical, nonclinical and patient—to support a comprehensive, balanced decision-making approach.
FDA will host a webinar on Thursday, February 23, 2017 to help manufacturers and other interested stakeholders understand the information provided in this final guidance document.  
Following a brief presentation, the FDA will respond to questions.
Webinar details:
Registration is not necessary.
  • Date: Thursday, February 23, 2017  
  • Time: 12:30 p.m. – 2 p.m. Eastern Time (please connect by 12:15 p.m.)
 To hear the presentation and ask questions:
Dial: 800-475-0553; passcode: 1759468 | International: 1-415-228-5009; passcode: 1759468
Conference number:
To view the slide presentation during the webinar:
Due to expected high participation of this webinar, please use the following link to access the live presentation if the previous link returns an error message upon logging in:
Following the webinar, a transcript, recording and slides will be available at: The slide presentation will be available at this site on the morning of the webinar.
If you have any questions regarding this guidance document, please contact CDRH’s Division of Industry and Consumer Education (DICE) at, or by phone 1-800-638-2041, or 301-796-7100.

Food and Drug Administration
Center for Devices and Radiological Health

No hay comentarios: